Saudi Pharmaceutical Industries and Medical Appliances Corporation (2070.SR)
SAR 31.65
(-0.32%)
SAR 31.65
(-0.32%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 153.97 Million SAR | 1154.9% |
| 2022 | -13.46 Million SAR | -110.2% |
| 2021 | 142.64 Million SAR | -52.3% |
| 2020 | 241.95 Million SAR | 231.31% |
| 2019 | -290.93 Million SAR | -611.88% |
| 2018 | 162.56 Million SAR | -84.46% |
| 2017 | 251.55 Million SAR | -39.39% |
| 2016 | 369.12 Million SAR | -12.13% |
| 2015 | 378.92 Million SAR | 45.48% |
| 2014 | 374.24 Million SAR | 4.05% |
| 2013 | 332.13 Million SAR | 15.7% |
| 2012 | 292.52 Million SAR | 40.64% |
| 2011 | 207.57 Million SAR | 26.24% |
| 2010 | 162.81 Million SAR | -11.43% |
| 2009 | 177.61 Million SAR | 258.71% |
| 2008 | -96.7 Million SAR | -8.98% |
| 2007 | -92.16 Million SAR | -200.45% |
| 2006 | 111.59 Million SAR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 107 Million SAR | 403.54% |
| 2024 Q2 | 51.67 Million SAR | -22.8% |
| 2023 Q3 | 5.82 Million SAR | -90.65% |
| 2023 Q1 | 97.67 Million SAR | 266.76% |
| 2023 FY | - SAR | 1154.9% |
| 2023 Q2 | 62.26 Million SAR | -36.25% |
| 2023 Q4 | -45 Million SAR | -873.2% |
| 2022 FY | - SAR | -110.2% |
| 2022 Q4 | -58.57 Million SAR | -7057.4% |
| 2022 Q3 | -818.38 Thousand SAR | 95.28% |
| 2022 Q1 | 63.26 Million SAR | 602.15% |
| 2022 Q2 | -17.33 Million SAR | -127.4% |
| 2021 Q4 | -12.59 Million SAR | -132.66% |
| 2021 Q2 | 58.27 Million SAR | 21.97% |
| 2021 FY | - SAR | -52.3% |
| 2021 Q3 | 38.58 Million SAR | -33.79% |
| 2021 Q1 | 47.77 Million SAR | 54.43% |
| 2020 Q1 | 57.56 Million SAR | 129.07% |
| 2020 Q3 | 77.49 Million SAR | 82.38% |
| 2020 FY | - SAR | 231.31% |
| 2020 Q4 | 30.93 Million SAR | -60.08% |
| 2020 Q2 | 42.48 Million SAR | -26.18% |
| 2019 Q2 | -74.39 Million SAR | -257.92% |
| 2019 FY | - SAR | -611.88% |
| 2019 Q3 | 49.82 Million SAR | 166.98% |
| 2019 Q4 | -198.01 Million SAR | -497.38% |
| 2019 Q1 | 47.11 Million SAR | 168.84% |
| 2018 Q3 | 3.57 Million SAR | -93.06% |
| 2018 Q1 | 69.52 Million SAR | 134.36% |
| 2018 FY | - SAR | -84.46% |
| 2018 Q4 | -68.43 Million SAR | -2016.49% |
| 2018 Q2 | 51.45 Million SAR | -26.0% |
| 2017 Q2 | 59.45 Million SAR | 15.49% |
| 2017 FY | - SAR | -39.39% |
| 2017 Q3 | 128.76 Million SAR | 116.59% |
| 2017 Q1 | 51.47 Million SAR | -78.17% |
| 2017 Q4 | -202.37 Million SAR | -257.16% |
| 2016 Q3 | 19.62 Million SAR | -69.01% |
| 2016 Q1 | 102.92 Million SAR | -60.88% |
| 2016 FY | - SAR | -12.13% |
| 2016 Q2 | 63.31 Million SAR | -38.48% |
| 2016 Q4 | 235.78 Million SAR | 1101.68% |
| 2015 Q2 | 245.03 Million SAR | 130.55% |
| 2015 Q1 | 106.28 Million SAR | 11.84% |
| 2015 Q3 | 34.35 Million SAR | -85.98% |
| 2015 FY | - SAR | 45.48% |
| 2015 Q4 | 263.06 Million SAR | 665.76% |
| 2014 Q4 | 95.03 Million SAR | 126.41% |
| 2014 Q3 | 41.97 Million SAR | -60.35% |
| 2014 Q2 | 105.85 Million SAR | 6.85% |
| 2014 Q1 | 99.06 Million SAR | 128.13% |
| 2014 FY | - SAR | 4.05% |
| 2013 Q1 | 70.64 Million SAR | 11.91% |
| 2013 Q3 | 44.28 Million SAR | -62.9% |
| 2013 Q4 | 43.42 Million SAR | -1.93% |
| 2013 FY | - SAR | 15.7% |
| 2013 Q2 | 119.35 Million SAR | 68.95% |
| 2012 Q4 | 63.12 Million SAR | 58.92% |
| 2012 FY | - SAR | 40.64% |
| 2012 Q3 | 39.72 Million SAR | 0.0% |
| 2011 FY | - SAR | 26.24% |
| 2010 FY | - SAR | -11.43% |
| 2009 FY | - SAR | 258.71% |
| 2008 FY | - SAR | -8.98% |
| 2007 FY | - SAR | -200.45% |
| 2006 FY | - SAR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Jamjoom Pharmaceuticals Factory Company | 338.64 Million SAR | 54.534% |